WGU D116 Advanced Pharmacology OA
Exam 2026/2027 Actual Exam - 200
Questions with Detailed Rationales |
Complete A+ Guide
Exam Blueprint:
Pharmacokinetics & Pharmacodynamics (15%) – 30 Qs
Cardiovascular & Renal Pharmacology (20%) – 40 Qs
Respiratory & Allergy Pharmacology (10%) – 20 Qs
Endocrine & Metabolic Pharmacology (15%) – 30 Qs
Neurologic & Psychiatric Pharmacology (15%) – 30 Qs
Infectious Disease & Antimicrobials (15%) – 30 Qs
Special Populations, Toxicology & Clinical Application (10%) – 20 Qs
Time limit (simulated): 3 hours (0.9 min/question)
Passing threshold: 70% (140/200)
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1–30)
1. Which of the following best describes pharmacokinetics?
A) The study of drug effects on the body
B) The study of drug absorption, distribution, metabolism, and excretion (ADME)
C) The study of drug toxicity
D) The study of drug interactions
Answer: B
Rationale: Pharmacokinetics (what the body does to the drug) encompasses ADME.
Pharmacodynamics (what the drug does to the body) is the study of drug effects.
2. The "first-pass effect" refers to:
,A) Rapid intravenous administration
B) Drug metabolism in the liver before reaching systemic circulation (primarily oral
drugs)
C) Drug excretion by the kidneys
D) Drug binding to plasma proteins
Answer: B
Rationale: The first-pass effect reduces bioavailability of oral drugs; some drugs (e.g.,
nitroglycerin, morphine) require higher oral doses or alternative routes.
3. Bioavailability is defined as:
A) The speed of drug absorption
B) The fraction of an administered dose that reaches systemic circulation unchanged
C) The volume of distribution
D) The half-life of the drug
Answer: B
Rationale: IV administration has 100% bioavailability; oral bioavailability is reduced by
first-pass metabolism and absorption.
4. Which route of administration has the highest bioavailability?
A) Oral
B) Subcutaneous
C) Intravenous (IV)
D) Intramuscular (IM)
Answer: C
Rationale: IV administration bypasses absorption barriers and first-pass metabolism,
delivering 100% of the dose to systemic circulation.
5. The volume of distribution (Vd) of a drug that is highly tissue-bound will be:
A) Low
B) High
C) Zero
D) Negative
Answer: B
,Rationale: High Vd indicates extensive tissue binding; low Vd indicates primarily plasma
binding. Vd affects loading dose.
6. A drug with a high volume of distribution (e.g., digoxin) is characterized by:
A) High plasma concentration
B) Low plasma concentration (distributes widely into tissues)
C) Rapid renal excretion
D) Minimal tissue binding
Answer: B
Rationale: High Vd means most drug is in tissues, not plasma; this requires large loading
doses to achieve therapeutic plasma levels.
7. The half-life (t½) of a drug is:
A) The time required for 50% of the drug to be eliminated
B) The time required for the drug to reach peak concentration
C) The time required for the drug to be completely eliminated
D) The time required for the drug to reach steady state
Answer: A
Rationale: Half-life determines dosing interval; it takes approximately 4-5 half-lives to
reach steady state and to eliminate the drug.
8. Steady state of a drug is typically reached after approximately:
A) One half-life
B) 2-3 half-lives
C) 4-5 half-lives
D) 10 half-lives
Answer: C
Rationale: Steady state is reached when rate of drug administration equals rate of
elimination, usually after 4-5 half-lives.
9. The loading dose of a drug is intended to:
A) Maintain steady state
B) Achieve therapeutic concentration rapidly
, C) Prolong half-life
D) Reduce side effects
Answer: B
Rationale: Loading doses quickly achieve therapeutic levels; maintenance doses keep
levels within therapeutic range.
10. Cytochrome P450 (CYP) enzymes are primarily located in which organ?
A) Kidney
B) Liver
C) Lungs
D) Intestine
Answer: B
Rationale: CYP enzymes (e.g., CYP3A4, 2D6, 2C9) are concentrated in the liver and are
responsible for phase I drug metabolism.
11. Which CYP enzyme is responsible for metabolizing the largest number of drugs?
A) CYP2D6
B) CYP1A2
C) CYP3A4
D) CYP2C9
Answer: C
Rationale: CYP3A4 metabolizes approximately 50% of all drugs, including statins, calcium
channel blockers, and many others.
12. A patient taking warfarin (CYP2C9 substrate) starts taking amiodarone (CYP2C9
inhibitor). The expected effect is:
A) Decreased warfarin levels
B) Increased warfarin levels (risk of bleeding)
C) No change in warfarin levels
D) Increased warfarin metabolism
Answer: B
Rationale: Amiodarone inhibits CYP2C9, decreasing warfarin metabolism, leading to
increased INR and bleeding risk.
Exam 2026/2027 Actual Exam - 200
Questions with Detailed Rationales |
Complete A+ Guide
Exam Blueprint:
Pharmacokinetics & Pharmacodynamics (15%) – 30 Qs
Cardiovascular & Renal Pharmacology (20%) – 40 Qs
Respiratory & Allergy Pharmacology (10%) – 20 Qs
Endocrine & Metabolic Pharmacology (15%) – 30 Qs
Neurologic & Psychiatric Pharmacology (15%) – 30 Qs
Infectious Disease & Antimicrobials (15%) – 30 Qs
Special Populations, Toxicology & Clinical Application (10%) – 20 Qs
Time limit (simulated): 3 hours (0.9 min/question)
Passing threshold: 70% (140/200)
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1–30)
1. Which of the following best describes pharmacokinetics?
A) The study of drug effects on the body
B) The study of drug absorption, distribution, metabolism, and excretion (ADME)
C) The study of drug toxicity
D) The study of drug interactions
Answer: B
Rationale: Pharmacokinetics (what the body does to the drug) encompasses ADME.
Pharmacodynamics (what the drug does to the body) is the study of drug effects.
2. The "first-pass effect" refers to:
,A) Rapid intravenous administration
B) Drug metabolism in the liver before reaching systemic circulation (primarily oral
drugs)
C) Drug excretion by the kidneys
D) Drug binding to plasma proteins
Answer: B
Rationale: The first-pass effect reduces bioavailability of oral drugs; some drugs (e.g.,
nitroglycerin, morphine) require higher oral doses or alternative routes.
3. Bioavailability is defined as:
A) The speed of drug absorption
B) The fraction of an administered dose that reaches systemic circulation unchanged
C) The volume of distribution
D) The half-life of the drug
Answer: B
Rationale: IV administration has 100% bioavailability; oral bioavailability is reduced by
first-pass metabolism and absorption.
4. Which route of administration has the highest bioavailability?
A) Oral
B) Subcutaneous
C) Intravenous (IV)
D) Intramuscular (IM)
Answer: C
Rationale: IV administration bypasses absorption barriers and first-pass metabolism,
delivering 100% of the dose to systemic circulation.
5. The volume of distribution (Vd) of a drug that is highly tissue-bound will be:
A) Low
B) High
C) Zero
D) Negative
Answer: B
,Rationale: High Vd indicates extensive tissue binding; low Vd indicates primarily plasma
binding. Vd affects loading dose.
6. A drug with a high volume of distribution (e.g., digoxin) is characterized by:
A) High plasma concentration
B) Low plasma concentration (distributes widely into tissues)
C) Rapid renal excretion
D) Minimal tissue binding
Answer: B
Rationale: High Vd means most drug is in tissues, not plasma; this requires large loading
doses to achieve therapeutic plasma levels.
7. The half-life (t½) of a drug is:
A) The time required for 50% of the drug to be eliminated
B) The time required for the drug to reach peak concentration
C) The time required for the drug to be completely eliminated
D) The time required for the drug to reach steady state
Answer: A
Rationale: Half-life determines dosing interval; it takes approximately 4-5 half-lives to
reach steady state and to eliminate the drug.
8. Steady state of a drug is typically reached after approximately:
A) One half-life
B) 2-3 half-lives
C) 4-5 half-lives
D) 10 half-lives
Answer: C
Rationale: Steady state is reached when rate of drug administration equals rate of
elimination, usually after 4-5 half-lives.
9. The loading dose of a drug is intended to:
A) Maintain steady state
B) Achieve therapeutic concentration rapidly
, C) Prolong half-life
D) Reduce side effects
Answer: B
Rationale: Loading doses quickly achieve therapeutic levels; maintenance doses keep
levels within therapeutic range.
10. Cytochrome P450 (CYP) enzymes are primarily located in which organ?
A) Kidney
B) Liver
C) Lungs
D) Intestine
Answer: B
Rationale: CYP enzymes (e.g., CYP3A4, 2D6, 2C9) are concentrated in the liver and are
responsible for phase I drug metabolism.
11. Which CYP enzyme is responsible for metabolizing the largest number of drugs?
A) CYP2D6
B) CYP1A2
C) CYP3A4
D) CYP2C9
Answer: C
Rationale: CYP3A4 metabolizes approximately 50% of all drugs, including statins, calcium
channel blockers, and many others.
12. A patient taking warfarin (CYP2C9 substrate) starts taking amiodarone (CYP2C9
inhibitor). The expected effect is:
A) Decreased warfarin levels
B) Increased warfarin levels (risk of bleeding)
C) No change in warfarin levels
D) Increased warfarin metabolism
Answer: B
Rationale: Amiodarone inhibits CYP2C9, decreasing warfarin metabolism, leading to
increased INR and bleeding risk.
